These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9815842)

  • 1. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment.
    Murray JL; Macey DJ; Grant EJ; Rosenblum MG; Kasi LP; Zhang HZ; Katz RL; Riger PT; LeBherz D; Bhadkamkar V
    Cancer Res; 1995 Dec; 55(23 Suppl):5925s-5928s. PubMed ID: 7493372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
    Meredith RF; Khazaeli MB; Macey DJ; Grizzle WE; Mayo M; Schlom J; Russell CD; LoBuglio AF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3254s-3258s. PubMed ID: 10541372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
    Murray JL; Macey DJ; Kasi LP; Rieger P; Cunningham J; Bhadkamkar V; Zhang HZ; Schlom J; Rosenblum MG; Podoloff DA
    Cancer; 1994 Feb; 73(3 Suppl):1057-66. PubMed ID: 8306248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
    Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
    Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.
    Tempero M; Leichner P; Dalrymple G; Harrison K; Augustine S; Schlam J; Anderson J; Wisecarver J; Colcher D
    J Clin Oncol; 1997 Apr; 15(4):1518-28. PubMed ID: 9193348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
    Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
    Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
    Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
    Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM
    Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
    J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.